DE ROOVER, Arnaud ; Centre Hospitalier Universitaire de Liège - CHU > Département de chirurgie > Chirurgie abdo, sénologique, endocrine et de transplantation
Germenis, A
Stavropoulos, C
Buckels, D
Mayer, D
Language :
English
Title :
The immunomodulatory effect of leflunomide in rat cardiac allotransplantation
Publication date :
September 1995
Journal title :
Transplantation
ISSN :
0041-1337
eISSN :
1534-6080
Publisher :
Lippincott Williams & Wilkins, United States - Maryland
Bartlett RR, Schleyerbach R. Immunopharmacological profile of a novel isoxazole derivative, HWA 486, with potential anti rheumatic activity: I. Disease modifying action on adjuvant arthritis in the rat. Int J Immunopharmacol 1985; 7: 7.
Thoenes GH, Sitter T, Langer KH, Bartlett RR, Schleyerbach R. Leflunomide (HWA 486) inhibits experimental auto immune tubulointerstitial nephritis in rats. Int J Immunopharmacol 1989; 11: 921.
Ogawa T, Inazu M, Gotoh K, Hayashi S. Effects of leflunomide on glomerulonephritis induced by anti basement membrane antibody in rats. Agents Actions 1990; 31: 321.
Bartlett RR, Dimitrijevic M, Zielinski T, et al. Leflunomide (HWA 486), a novel immunomodulating compound for the treatment of auto immune disorders and reactions leading to transplantation rejection. Agents Actions 1991; 32: 10.
Chong AS, Finnegan A, Jiang X, et al. Leflunomide, a novel immunosuppressive agent. The mechanism of inhibition of T cell proliferation. Transplantation 1993; 55: 1361.
Kuchle CC, Thoenes GH, Langer KH, Schorlemmer H-U, Bar tlett RR, Schleyerbach R. Prevention of kidney and skin graft rejection in rats by leflunomide, a new immunomodulating agent. Transplant Proc 1991; 23: 1083.
Schorlemmer H-U, Seiler FR, Bartlett RR. Prolongation of allo geneic transplanted skin grafts and induction of tolerance by leflunomide, a new immunosuppressive isoxazol derivative. Transplant Proc 1993; 25: 763.
Williams JW, Xiao F, Foster P, et al. Leflunomide in experimen tal transplantation. Control of rejection and alloantibody production, reversal of acute rejection, and interaction with cyclosporine. Transplantation 1994; 57: 1223.
Xiao F, Chong A, Foster P, et al. Leflunomide on acute rejection in hamster to rat cardiac xenografts. Abstract 131. Cambridge, UK: Second International Congress on Xenotransplantation, 1993: 160.
Wright JR, Kearns H, MacDonald AS. Leflunomide prolongs fish-to-mouse islet xenograft survival in BALB/C mice [Abstract 117]. Cambridge, UK: Second International Congress on Xenotransplantation, 1993: 146.
Ono K, Lindsey ES. Improved techniques of heart transplant in rats. J Thorac Cardiovasc Surg 1969; 57: 225.
White DJG, Rolles K, Ottawa T, Turell O. Cyclosporin A induced long-term survival of fully incompatible skin and heart grafts in rats. Transplant Proc 1980; 12: 261.
Nagao T, White DJG, Caine RY. Kinetics of unresponsiveness induced by a short course of cyclosporin A. Transplantation 1982; 33: 31.
Lim SML, White DJG, Caine RY. Identifying a susceptible pe riod following cyclosporine A induced tolerance of heart grafts in the rat. Transplant Proc 1987; 19: 4218.
Bartlett RR, Zielinski T, Schorlemmer H-Ulrichs. Nonsteroidal anti-inflammatory drugs. In: Lewis AJ, Furst DE, eds. Leflunomide: a novel immunomodulating drug. New York: Marcel Dekker, Inc., 1994: 349.
Ulrichs K, Kaitschick J, Bartlett R, Muller Ruchholtz W. Sup pression of natural xenophile antibodies with the novel immunomodulating drug leflunomide. Transplant Proc 1992; 24: 718.
Homan WP, Fabre JW, Williams KA, Millard PR, Morris PJ. Studies on the immunosuppressive properties of cyclosporin A in rats receiving renal allografts. Transplantation 1980; 29: 361.
Dunn DC, White DJG, Wade J. Survival of first and second kidney allografts after withdrawal of cyclosporin A. IRCS Med Sci 1978; 6: 464.
Hall BM, Jelbart ME, Gurley KE, Dorsch SE. Specific unrespon-sivenes in rats with prolonged cardiac allograft survival after treatment with cyclosporine: mediation of specific suppression by T helper/inducer cells. J Exp Med 1985; 162: 1683.
Tilney NL, Padberg WM, Lord RHH, et al. Synergy between subtherapeutic doses of cyclosporin and immunological manipulations in rat heart graft recipients. Transplantation 1988; 46: 122S.
Kostakis AJ, White DJG, Caine RY. Prolongation of rat heart allograft survival by cyclosporin A. IRCS Med Sci 1977; 5: 280.
Ochiai T, Nakajima K, Nagata M, Hiri S, Asano T, Isono K. Studies on the induction and maintenance of long-term graft acceptance by treatment with FK506 in heterotopic cardiac allotransplantation in rats. Transplantation 1987; 44: 734.
Green CJ, Allison AC. Extensive prolongation of rabbit kidney allograft survival after short-term cyclosporin treatment. Lancet 1978; 1: 1182.
White DJG, Caine RY. Cyclosporin A in heart allografting: its immunosuppressive and tolerance inducing properties. Heart Transplant 1982; 1: 102.
Collier DStJ, Caine RY, de Curtins M, et al. Alternate day cylosporin A and azathioprine in experimental dog renal allografts. Transplant Proc 1987; 19: 1279.
Prop J, Nieuwenhuis P, Wildevuur CRH. Lung allograft rejec tion in the rat. Transplantation 1985; 40: 25.
Webtra AL, Petersen AH, Prop J, Wildevuur CRH. Cyclosporin therapy for treatment of rat heart allograft rejection. Transplant Proc 1989; 21: 963.
